Efficacy and safety of low-dose interleukin-2 in combination with methotrexate in patients with active rheumatoid arthritis: a randomized, double-blind, placebo-controlled phase 2 trial

Rheumatoid arthritis (RA) is an aggressive autoimmune arthritis, and current therapies remain unsatisfactory due to low remission rate and substantially adverse effects. Low-dose interleukin-2 (Ld-IL2) is potentially a therapeutic approach to further improve the disease. This randomized, double-blin...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xiaoying, Miao, Miao, Zhang, Ruijun, Liu, Xu, Zhao, Xiaozhen, Shao, Miao, Liu, Tian, Jin, Yuebo, Chen, Jiali, Liu, Huixin, Zhang, Xia, Li, Yun, Zhou, Yunshan, Yang, Yue, Li, Ru, Yao, Haihong, Liu, Yanying, Li, Chun, Li, Yuhui, Ren, Limin, Su, Yin, Sun, Xiaolin, He, Jing, Li, Zhanguo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8898945/
https://www.ncbi.nlm.nih.gov/pubmed/35250032
http://dx.doi.org/10.1038/s41392-022-00887-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8898945/
https://www.ncbi.nlm.nih.gov/pubmed/35250032
http://dx.doi.org/10.1038/s41392-022-00887-2

Ejemplares similares